RBC Bioscience Corporation (6848) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for RBC Bioscience Corporation (6848:TWSE), powered by AI.

Current Price
$20.50
P/E Ratio
13.6
Market Cap
293M
Sector
Healthcare
What is the RBC Bioscience Corporation stock price forecast?

RBC Bioscience Corporation is currently trading at $20.50. View real-time AI analysis on Alpha Lenz.

What is RBC Bioscience Corporation insider trading activity?

View the latest insider trading data for RBC Bioscience Corporation on Alpha Lenz.

What is RBC Bioscience Corporation's P/E ratio?

RBC Bioscience Corporation's P/E ratio is 13.6.

RBC Bioscience Corporation

TWSE · 6848
NT$20.50-0.35(-1.68%)
Ask about RBC Bioscience Corporation's future dividend policy...
Alpha Chat Insight

RBC Bioscience Corporation trades at a P/E of 13.6 (undervalued) with solid ROE of 8.8%.

Ask for details

Company Overview

RBC Bioscience Corporation is a biotechnology company specializing in the research, development, manufacturing, and sale of reagents and devices for life science and molecular diagnostics. Its primary function is to provide advanced tools for nucleic acid extraction and purification, including automated instruments equipped with ultraviolet sterilization systems and disposable reagent kits designed to enhance the efficiency and purity of DNA and RNA extraction. These products play a crucial role in clinical diagnostics, biomedical research, disease prevention, forensic testing, and genetic analysis, serving medical laboratories, research institutions, and healthcare providers across Europe, Asia, America, Africa, Australia, and Taiwan. Founded in 1995 and based in New Taipei City, Taiwan, RBC Bioscience is ISO9001 and CE certified, reflecting its commitment to high-quality manufacturing standards. The company's focus on innovation supports the molecular diagnostic sector by enabling reliable sample processing for applications such as disease tracking, treatment planning, and scientific discovery, making it a significant contributor to the global healthcare equipment and supplies market.

SectorHealthcare
IndustryBiotechnology
Employees52

Company Statistics

FY 2024

Profile

NT$292.60MMarket Cap
NT$205.25MRevenue
0.00Shares Out
52Employees

Margins

47.78%Gross
27.17%EBITDA
17.44%Operating
13.14%Pre-Tax
10.51%Net

Valuation

13.57P/E
1.17P/B
1.43EV/Sales
12.39EV/EBITDA
6.42P/FCF

Growth (CAGR)

-6.51%Rev 3Yr
4.89%Rev 5Yr
-9.46%Op Inc 3Yr
12.84%Op Inc 5Yr
-9.12%Net Inc 3Yr
8.33%Net Inc 5Yr

Returns

2.84%ROA
8.80%ROE
4.91%ROIC

Financial Health

NT$79.86MCash & Cash Equivalents
NT$434.72MNet Debt
206.41%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

RBC Bioscience Corporation (ticker: 6848) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 52 employees. Market cap is $293M.

The current price is 20.5 with a P/E ratio of 13.57x and P/B of 1.17x.

ROE is 8.80% and operating margin is 17.44%. Annual revenue is $205M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
RBC Bioscience Corporation (6848) Stock Forecast 2026 $20.50 — Price, Financials & Analyst Targets | Alpha Lenz